StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX – Get Rating) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, Bank of America lowered shares of Athersys from a buy rating to an underperform rating and dropped their price objective for the stock from $1.00 to $0.25 in a report on Monday, May 23rd.
NASDAQ:ATHX opened at $0.24 on Friday. Athersys has a 12-month low of $0.18 and a 12-month high of $1.81. The firm has a market capitalization of $60.98 million, a PE ratio of -0.69 and a beta of -1.29. The firm has a 50-day moving average price of $0.38 and a 200 day moving average price of $0.65.
Several hedge funds and other institutional investors have recently bought and sold shares of ATHX. Private Advisor Group LLC acquired a new stake in shares of Athersys during the first quarter worth approximately $27,000. Claraphi Advisory Network LLC increased its holdings in shares of Athersys by 47.8% during the fourth quarter. Claraphi Advisory Network LLC now owns 34,000 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 11,000 shares in the last quarter. Tobias Financial Advisors Inc. acquired a new stake in shares of Athersys during the first quarter worth approximately $36,000. ProShare Advisors LLC grew its stake in shares of Athersys by 70.5% during the fourth quarter. ProShare Advisors LLC now owns 44,739 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 18,495 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Athersys by 32.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 46,490 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 11,387 shares during the last quarter. 22.39% of the stock is owned by institutional investors.
About Athersys (Get Rating)
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
- Get a free copy of the StockNews.com research report on Athersys (ATHX)
- 3 Education Stocks to Enroll in This Summer
- The Institutions Get Comfortable With The Lovesac Company
- McDonald’s Might Just Be The Best Recession Proof Stock
- Basset Furniture Quietly Proves Its Value
- Earnings Revisions: Why You Shouldn’t Count On A Rebound In Stocks … Yet
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.